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Glioblastoma multiforme (GBM) is the most common primary brain tumor.  
Studies have shown that targeting the DNA damage response can sensitize cancer cells to 
DNA damaging agents.  Ataxia telangiectasia mutated (ATM) is involved in signaling 
DNA double strand breaks.  Our group has previously shown that ATM inhibitors 
(ATMi) sensitize GBM cells and tumors to ionizing radiation.  This effect is greater when 
the tumor suppressor p53 is mutated.    
 
The goals of this work include validation of a new ATM inhibitor, AZ32, and 
elucidation of how ATMi and p53 status interact to promote cell death after radiation.  
We propose that ATMi and radiation induce mitotic catastrophe in p53 mutants by 
overriding cell cycle arrest.  We tested this hypothesis in human colon carcinoma and 
glioma cells that differ only in p53 status.   
xiv 
 
We found that AZ32 effectively inhibits phosphorylation of ATM targets.  In 
addition, AZ32 significantly sensitizes glioma cells to ionizing radiation.  While HCT116 
colon carcinoma cells fail to arrest the cell cycle after radiation, their response to ATMi 
differs from that in gliomas.  Indeed, wild type HCT116 cells were more sensitive than 
p53 mutants to ionizing radiation in the presence of ATMi.  In contrast, ATMi 
significantly radiosensitized glioma cells in which p53 is knocked down.  Live cell 
imaging confirmed that radiation and ATMi preferentially induce mitotic catastrophe in 
p53-deficient cells.  We conclude that p53-deficient cells rely on ATM signaling for 
G2/M cell cycle arrest.  We propose a model of G2/M arrest whereby ATM and p53-
dependent signaling pathways converge to ultimately inhibit Cdc25 phosphatases.    
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I. Introduction 
 
1.1 Glioblastoma Multiforme 
 Glioblastoma Multiforme (GBM) is the most common form of primary brain 
tumor (Dunn et al., 2012).  GBM originates from the glial cells in the brain and is among 
the most debilitating and lethal forms of cancer.  First-line treatment consists of surgical 
resection, radiation, and adjuvant chemotherapy (Stupp et al., 2005).  Yet, in addition to 
being highly resistant to radio- and chemotherapies, GBM tumors are extremely 
aggressive and readily invade surrounding neural tissue, which limits the utility of 
surgical intervention (Cuddapah et al., 2014).  Not surprisingly, the average GBM patient 
survives only 12 to 15 months post-diagnosis (Cloughesy et al., 2014; Stupp et al., 2005).  
Thus, there is a critical need for more efficacious treatments that specifically target tumor 
cells and yield longer-term improvements in patient survival. 
 
1.2 Targeting the DNA Damage Response in GBM 
Radiation and most cytotoxic chemotherapeutics work by inhibiting DNA 
replication or directly damaging DNA.  The major forms of DNA aberrations include 
base damage, backbone damage, and intra- or inter-strand crosslinks.  The process by 
which cells detect damage and transduce signals to stimulate repair is termed the DNA 
damage response (DDR).  The two major signaling and detection proteins involved in 
DDR are the ataxia telangiectasia mutated (ATM) and ATM/Rad3-related (ATR) kinases 
(Cimprich and Cortez, 2008; Shiloh and Ziv, 2013).  In the absence of damage, ATM 
exists as an inactive dimer that rapidly dissociates in to active monomers upon 
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autophosphorylation at serine-1981, which stabilizes the protein at the sites of DNA 
double strand breaks (DSBs) (Bakkenist and Kastan, 2003; So et al., 2009).  In general, 
DSBs—which most often result from ionizing radiation and radiomimetic drugs—are 
detected by a complex including the proteins Mre11, Rad50, and Nbs1 (MRN complex), 
which recruits ATM to damage sites and stimulates its autophosphorylation (Lavin, 
2007).  UV-induced base damage, crosslinks, and single-strand breaks (SSBs), on the 
other hand, induce phosphorylation and activation of ATR, which associates directly at 
the sites of DNA lesions (Bomgarden et al., 2004; Cimprich and Cortez, 2008; Liu et al., 
2011).  Once activated, ATM and ATR go on to phosphorylate a variety of substrates 
involved in slowing cell growth, halting cell division, and stimulating DNA repair 
(Discussed in later sections).   
 
It is thought that cancer can manipulate the DDR to enhance radio- and chemo-
resistance and promote survival (Bao et al., 2006; Bouwman and Jonkers, 2012).  As 
such, it may be possible to increase cancer’s sensitivity to DNA damaging agents (DDAs) 
by disrupting the DDR.  It is widely documented that cells lacking ATM (i.e., A-T cells) 
are highly sensitive to ionizing radiation (IR) (Littlefield et al., 1981; McKinnon, 1987; 
Nayler et al., 2012; Taylor et al., 1975).  Members of our group hypothesized that 
pharmacological inhibition of ATM would sensitize glioma cells to IR (Golding et al., 
2009).  They found that treatment with an ATM inhibitor (ATMi), KU-60019, prior to IR 
significantly radiosensitized multiple human glioma cell lines.  They also showed that 
KU-60019 effectively reduced in-vitro invasion and migration in the same cells.  Another 
study found that extremely low concentrations of KU-60019 were sufficient to sensitize 
3 
 
U1242 and U373 human glioma cells to IR (Golding et al., 2012).  Of particular interest 
is that both U1242 and U373 harbor mutations in p53, a prominent ATM substrate. 
 
The p53 tumor suppressor, widely considered the “guardian of the genome”, is a 
393-amino acid protein involved in a variety of cellular functions, including cell cycle 
arrest, DNA repair, apoptosis, and senescence, among others (Freed-Pastor and Prives, 
2012; Muller and Vousden, 2013, 2014; Wei et al., 2006).  Its structure consists of two 
acidic N-terminal transactivation domains, a proline-rich region, a central DNA-binding 
domain, an oligomerization domain, and a basic C-terminal regulatory domain.  Wild-
type p53 exists as a tetrameric transcription factor that binds DNA and modulates 
expression of many genes involved in cell growth and division (Wei et al., 2006).  p53 
also transactivates genes that regulate its own signaling, such as MDM2, an E3-ubiquitin 
ligase that marks p53 for degradation and binds its N-terminus to reduce transcription of 
target genes (Barak et al., 1993; Kubbutat et al., 1997; Momand et al., 1992). 
 
p53 is the most prevalently mutated gene in human cancers (Freed-Pastor and 
Prives, 2012; Kandoth et al., 2013; Muller and Vousden, 2013, 2014).  Nonsense and 
truncation mutants that fail to express any p53 protein are common; however, the bulk of 
mutations occur as single-amino acid missense substitutions.  Such modifications occur at 
the highest frequency within p53’s central DNA binding domain, and the most commonly 
mutated residues include R248, R273, R175, G245, R249, and R282 (Freed-Pastor and 
Prives, 2012; Harris and Hollstein, 1993).  Mutant forms of p53 can exert dominant 
negative effects, possibly through their ability to oligomerize with the wild-type protein.  
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In addition, loss-of-heterozygosity at the p53 locus is common among mutants, 
suggesting possible selection pressures that favor the development of mutations at both 
alleles (Burns et al., 1991; Campo et al., 1991; Nigro et al., 1989; Shetzer et al., 2014).  
 
It has been reported that overexpression of mutant p53 can transform cells, and 
individuals with germline mutations in p53 suffer from Li-Fraumeni syndrome, an 
autosomal-dominant disorder characterized by increased susceptibility to a variety of 
malignancies (Donninger et al., 2008; Eliyahu et al., 1984).  More than 50% of all human 
tumors have been found to carry mutations in p53, and p53-null and mutant mice are 
significantly more likely to develop tumors than their wild-type counterparts 
(Donehower, 1996; Nigro et al., 1989; Olive et al., 2004; Vogelstein et al., 2000).  
Evidence suggests that p53 mutants display many characteristics that may contribute to 
enhanced tumorigenicity.  For example, studies have associated expression of mutant p53 
with increased tumor cell proliferation, enhanced resistance to ionizing radiation and 
chemotherapy, heightened levels invasion and metastasis, and reduced patient survival 
(Fiorini et al., 2015; Hundley et al., 1997; Muller et al., 2011; Murakami et al., 2000; 
Reles et al., 2001).  p53 mutations have also been linked to genetic instability and cell 
cycle defects (Fukasawa et al., 1997; Hundley et al., 1997; Kuerbitz et al., 1992; 
Livingstone et al., 1992) .  Indeed, it may be possible to exploit the unique characteristics 
of p53 mutants to develop targeted cancer therapies. 
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1.3 Synthetic Lethality in p53 Mutant GBMs 
Synthetic lethality refers to the phenomenon whereby disruption of two or more 
genes results in a cell with an unviable phenotype.  The concept originates from 
microbial genetic theory, but it has recently received attention for its applications to 
treating cancer.  Assuming cancer cells harbor one or more known mutations—and that 
most “normal” cells do not—it should be possible to kill malignant cells and spare 
functional tissue with therapies targeting mutated genes and proteins.  Theoretically, it 
may be possible to identify treatments that induce synthetic lethality only in p53 mutants. 
 
As noted earlier, pharmacological inhibition of ATM sensitizes glioma cells to 
ionizing radiation (Golding et al., 2009, 2012). It is interesting to consider whether this 
effect varies between p53 mutant and wild-type tumors.  Indeed, our group has shown 
both in vitro and in vivo that the radiosensitizing effects of ATMi are greater in gliomas 
overexpressing mutant p53 relative to parental, p53 wild-type cells (Biddlestone-Thorpe 
et al., 2013; Golding et al., 2009). Similarly, dual therapy with radiation and ATMi 
significantly reduced tumor growth and increased survival of orthotopic p53-mutant-
glioma model mice, but not untreated mice or those with p53-wild type gliomas.  Thus, it 
may be possible to sensitize p53 mutant cells to DDAs using drugs that disrupt the 
normal DDR.   
 
While such results are promising, the mechanism by which ATMi radiosensitizes 
p53 mutant gliomas is unclear.  It is possible that the observed effects are due to 
variations in cell cycle regulation between p53 wild-type and defective cells.  The 
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following sections describe the cell cycle and its relation to the DNA damage checkpoints 
and p53 signaling.  The chapter concludes with a discussion of how p53 and ATM may 
interact within the cell cycle to determine glioma radiosensitivity.  
 
1.4 The Cell Cycle 
The eukaryotic cell cycle is characterized by four distinct stages: G1, S, G2 and M 
phases.  Cells typically spend most of their life cycles in G1 and it is in this stage that 
they synthesize biomolecules necessary to their functions within active tissue.  In 
terminally differentiated, non-dividing cells this phase of the cell cycle is often referred to 
as G0.  G1 is also when cells synthesize the biomolecules necessary in S-phase, during 
which DNA is replicated.  S-phase is followed by G2, which is characterized by rapid 
growth and protein synthesis.  Cells contain four copies of each chromosome during G2, 
so the total DNA content is twice of what it is G1 or G0. The G1/G0, S, and G2 phases 
are collectively referred to as interphase.  The period during which a cell actually divides 
is referred to as mitosis, or M-phase.  M-phase immediately follows G2 and proceeds 
through a series of four sub-phases.  Chromosomes condense and the nuclear envelope 
begins to break down during prophase.  Chromosomes align along the midline of the cell 
during metaphase and migrate to opposite poles during anaphase.  Telophase is when the 
cell membrane furrows and divides along the midline to form two new, genetically 
identical daughter cells.  At the end of mitosis, each daughter cell contains two identical 
copies of every chromosome.   
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The transitions between each stage of the cell cycle are characterized by distinct 
signaling mechanisms.  The primary proteins mediating these transitions include the 
cyclins and cyclin-dependent kinases (CDKs).  CDKs phosphorylate different cell-cycle 
proteins through hydrolysis of ATP and their function depends upon association with 
specific cyclins (Arellano and Moreno, 1997; Hochegger et al., 2008).  Intracellular CDK 
levels remain fairly stable throughout the cell cycle, while cyclin levels typically 
fluctuate, and different CDK/cyclin pairs are active at different stages of the cell cycle.  
Levels of D-type cyclins and CDK 4 and 6 activity are highest during G1 phase and 
decrease as the cell approaches the S-phase transition.  Cyclin E and CDK2 activity 
begins to increase during late G1 and peaks at the beginning of S-phase.  Cyclin E is 
degraded in S-phase as cyclin A expression and Cdc2 (human homolog of CDK1) 
activity begin to increase.  In contrast, cyclin A degradation and increased cyclin B 
expression is concomitant with the beginning of M-phase.  Cdc2 activity and cyclin B 
levels remain high until the end of metaphase, when activation of the anaphase-
promoting complex (APC/C) results in cyclin B ubiquitination and degradation 
(Buschhorn and Peters, 2006).  Thus, B-type cyclins are depleted upon completion of 
mitosis and the cell cycle starts anew.   
 
Entry in to S-phase is dependent upon the activity of CDKs 4, 6, and 2.  During 
G1, the retinoblastoma (Rb), p107, and p130 proteins bind E2F-family transcription 
factors in the HDAC repressor complex, inhibiting entry in to S-phase (Arellano and 
Moreno, 1997; Cao et al., 1992; Chellappan et al., 1991; Cobrinik et al., 1993; Dick and 
Rubin, 2013; Hochegger et al., 2008; Hurford et al., 1997).  Furthermore, 
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phosphorylation of the CDKs reduces their ability to bind cyclins and phosphorylate 
substrates.  Increased activity of Cdc25a phosphatase relieves CDK phosphorylation, 
resulting in hyperphosphorylation of Rb, p107, and p130 by Cyclin D-CDK4/6 and cyclin 
E-CDK2 in the cell’s nucleus (Dick and Rubin, 2013; Giacinti and Giordano, 2006).  
This releases E2F from its inhibitory complex and allows it to stimulate expression of 
genes involved in DNA replication.   
 
M-phase entry is stimulated by activation of cyclin B-Cdc2.  Inhibitory 
phosphorylation by kinases Wee1 and Myt1 keeps Cdc2 inactive in non-mitotic cells 
(Booher et al., 1997; Den Haese et al., 1995; Parker and Piwnica-Worms, 1992).  Around 
the beginning of M-phase, Aurora Kinase A (AURKA) activates Polo-like Kinase 1 
(PLK1), which goes on to phosphorylate the phosphatase Cdc25c and promotes its 
translocation in to the nucleus (Bruinsma et al., 2014; Macůrek et al., 2008; Toyoshima-
Morimoto et al., 2002).  In addition, Cdc25b is directly phosphorylated and activated by 
AURKA (Cazales et al., 2005; Dutertre et al., 2004).  Phosphorylated Cdc25, in turn, 
dephosphorylates Cdc2 to promote mitotic entry.  
 
1.5 ATM/ATR Signaling in Cell Cycle Checkpoints 
Detection of DNA damage can arrest the cell cycle at the G1/S or G2/M 
transitions or within S-phase.  Figure 1-1 illustrates cell cycle regulation through ATM 
and ATR signaling.  DSBs detected in G1 activate ATM, which goes on to phosphorylate 
many substrates, including p53 and the checkpoint kinase, Chk2 (Banin et al., 1998; 
Chaturvedi et al., 1999).  SSBs and base damage activate ATR, which in turn 
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phosphorylates p53 and the checkpoint kinase Chk1 (Smith et al., 2010).  Phosphorylated 
Chk1 and Chk2 then phosphorylate Cdc25a, which inactivates the phosphatase and marks 
it for ubiquitination and degradation (Busino et al., 2004; Mailand et al., 2000; Smith et 
al., 2010). Since Cdc25a activity is necessary for activation of CDKs 2, 4, and 6, 
phosphorylation by Chk1 and Chk2 prevents the transition from G1 to S phase, resulting 
in cell cycle arrest.   
 
DSBs detected in S-phase initiate a similar response as those detected in G1, 
whereby phosphorylation of Cdc25a inhibits CDK2 function.  Inhibition of CDK2 
prevents activation of Cdc45, which binds origins of replication and is necessary for 
initiation of DNA synthesis (Falck et al., 2002).  ATM can also phosphorylate histone 
H2AX, 53BP1, BRCA1, FANCD2, NBS1, and SMC1, which form distinct foci at sites of 
DSBs (Burma et al., 2001; Gatei et al., 2001; Harding et al., 2011; Lim et al., 2000; 
Taniguchi et al., 2002; Yazdi et al., 2002).  Interestingly, ionizing radiation and chemical 
stressors slow down DNA replication in normal cells; however, ATM-deficient cells 
maintain continuous rates of DNA replication following stress, a phenomenon referred to 
as radioresistant DNA synthesis (Painter, 1981).   
  
ATR is involved in signaling replication fork stalling, SSBs, and base damage 
during S-phase.  ATR associates with ATR interacting protein (ATRIP) and the pair 
localize to sites of damage through interactions with replication protein A (RPA), which 
associates with single-stranded DNA (Zou and Elledge, 2003).  The localized ATR-
ATRIP complex activates Chk1, which phosphorylates Cdc25a and, thus, inhibits DNA 
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synthesis through disruption of Cdc45 function (Smith et al., 2010).  ATR-ATRIP may 
further reduce replication fork progression by reducing the kinase activity of cdc7-Dbf4, 
which is involved in loading of Cdc45 on to chromatin (Costanzo et al., 2003).   
 
The G2/M checkpoint similarly proceeds through ATM and ATR and respective 
checkpoint kinases Chk2 and Chk1.  Rather than stimulating Cdc25 degradation, 
however, activation of the checkpoint kinases in G2 results in phosphorylation of 
Cdc25B/C, which promotes association with 14-3-3 protein and subsequent nuclear 
export and sequestration to the cytosol, preventing activation of cyclin B-Cdc2 (Donzelli 
and Draetta, 2003).  The activity of Wee1, which inhibits cyclin B-Cdc2 activity, is also 
enhanced through phosphorylation by Chk1 (O’Connell et al., 1997).  Altogether, it 
seems that ATM and ATR work in concert to prevent progression from G2 to M-phase. 
 
1.6 Functions of p53 in G1/S and G2/M Checkpoints 
DNA damage results in post-transcriptional modification and activation of p53.  
Evidence indicates that phosphorylation of p53 at serine-15 by ATM, ATR, and other 
enzymes can arrest the cell cycle to allow for DNA repair (Banin et al., 1998; Lees-Miller 
et al., 1992; Shieh et al., 2000; Tibbetts et al., 1999).  In the event that damage is too 
extensive, p53 is thought to directly and indirectly stimulate apoptosis (Fridman and 
Lowe, 2003).  Studies show that p53 is involved in maintaining cell cycle arrest at the 
G1/S transition.  Indeed, there is a correlation between expression of wild-type p53 and 
G1 arrest following gamma irradiation (Kuerbitz et al., 1992; Livingstone et al., 1992).  
In contrast, G1/S arrest is impaired in cells expressing mutant p53.  It appears that p53-
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mediated G1/S arrest depends primarily on enhanced expression of the CDK inhibitor 
p21 (Brugarolas et al., 1995, 1998; Harper et al., 1995).  p21 halts entry in to S-phase by 
associating with and inactivating cyclin A-CDK2 and cyclin E-CDK2 complexes.  This 
prevents hyperphosphorylation of Rb, p107, and p130, thus inhibiting release of E2F 
from the HDAC repressor complex.  p53 has also been shown to contribute to 
maintenance of G2/M arrest.  It has been reported that irradiated HCT116 cells with wild-
type p53 can effectively sustain G2/M arrest, while isogenic p53-null cells appear to 
continue cycling through mitosis (Bunz, 1998).  Cells null for p21 were also defective in 
their ability to sustain G2/M arrest after IR.  Furthermore, activated p53 induces 
expression of 14-3-3σ protein, which binds Cdc25 phosphatases, preventing their 
relocation to the nucleus and inhibiting activation of the cyclin B1/Cdc2 complex 
(Hermeking et al., 1997).  p53 also upregulates expression of another protein, GADD45, 
which has been shown to disrupt the interaction between cyclin B1 and Cdc2 (Jin et al., 
2002).  A specific form of GADD45, GADD45α, promotes cytosolic sequestration of 
Cdc25B/C and is upregulated after treatment with DDAs (Reinhardt et al., 2010).  
 
1.7 Cell Cycle Defects in p53 Mutants  
Given p53’s involvement in maintaining cell cycle arrest, one would predict p53 
mutants to continue dividing even in the presence of DNA damage.  If damage results in 
cells with chromosome breaks and if such cells divide to produce nonviable daughters 
with numerical aberrations, then DDAs should be more harmful to p53 mutants than to  
wild-type cells.  Yet, the relationship is not so simple, and there is evidence that some 
p53 mutant cells may even display a radioresistant phenotype (Lee and Bernstein, 1993).   
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Figure 1-1: Induction of cell cycle arrest through ATM and ATR signaling.  DNA 
damage activates ATR and/or ATM, which phosphorylate and activate p53 and the 
checkpoint kinases Chk1 and Chk2.  Phosphorylation of Cdc25 phosphatases by Chk1/2 
leads to their degradation or nuclear export, while phosphorylation of p53 induces 
transcription of its target genes.  These processes work in conjunction to arrest the cell 
cycle and inhibit cell division. 
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It is possible that p53 mutants utilize alternative, p53-independent pathways to arrest the 
cell cycle following DNA damage.  Indeed, it has been observed that p53 wild-type 
glioma cells arrest in G1 following irradiation, while those overexpressing mutant p53 
(D281G) tend to arrest in G2/M (Biddlestone-Thorpe et al., 2013).  Others have found 
that inhibition of ATM-dependent signaling through the p38MAPK-MK2 pathway 
sensitizes p53 mutants to the DDA doxorubicin and induces mitotic catastrophe 
(Reinhardt et al., 2007).  p38 phosphorylates and inactivates Cdc25B and Cdc25C, 
resulting in their nuclear export through association with 14-3-3 protein (Donzelli and 
Draetta, 2003).  While direct function of ATM in the p38MAPK-MK2 pathway is 
currently unknown, we expect it is linked through the thousand-and-one kinases 
(TAOKs) (Beckta et al., 2014).  ATM phosphorylates the TAOKs following DNA 
damage and the TAOKs go on to phosphorylate MEK3 and MEK6, which are the 
primary enzymes necessary for activating p38 (Raman et al., 2007).  Thus, mp53 cells do 
apparently have alternative mechanisms by which they can inhibit mitosis following 
DNA damage, and inactivating these mechanisms can promote cell death.  Figure 1-2 
illustrates an abbreviated model we have proposed to describe G2/M arrest in response to 
DSBs.  According to this model, ATM signaling through Chk2, p53, and p38MAPK-
MK2 is responsible for inhibiting mitosis following IR.   
 
We suspect that ATMi overcomes p53-independent modes of cell cycle arrest, 
allowing cells to divide in the presence of DNA damage.  Members of our group have 
shown that dual treatment of HCT116 human colon carcinoma cells with ATM inhibitor, 
AZ32, and radiation increases the frequency of condensed and/or malformed nuclei when 
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Figure 1-2: A mechanism describing ATM-mediated G2/M arrest.  Following DNA 
damage, ATM activates p53, Chk2, and the TAOKs/p38MAPK-MK2, inducing G2/M 
arrest through inhibition of Cdc25 phosphatases.  p53 activation may be ATM-dependent 
or independent.  p53 mutants depend entirely upon ATM to arrest mitosis.  Inactivation 
of both ATM-dependent and independent pathways results in aberrant mitosis. Arrows: 
Black = Activation; Red = Inhibition. Adapted from (Beckta et al., 2014). 
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 Figure 1-3:  ATMi enhances aberrant mitosis in p53-null HCT116 cells.  HCT116 
p53+/+ and -/- cells were treated with 3 µM AZ32 with or without 4 Gy radiation and 3 
days later examined for normal and aberrant mitotic figures by DAPI stain. Cells with 
condensed chromatin and nuclear morphology indicative of mitosis were counted.  
Control -/- cells show a 2-fold elevated mitotic frequency relative to +/+ cells, whereas 
irradiated +/+ cells have no mitotic events after IR. AZ32 with IR increased the 
frequency of aberrant mitotic figures and polyploidy only in -/- cells.  Numerical inserts 
indicate the proportion of aberrant to total mitoses. (K. Valerie, unpublished) 
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Figure 1-4: Increased mitotic aberrations in glioma cells exposed to ATMi and IR. 
Irradiated U1242 cells treated with AZ32 show increased centrosomes and anaphase 
bridges relative to untreated cells (A) and >2-fold over IR alone (B).  (J. Beckta, 
unpublished) 
17 
 
p53 is absent, but not when it is normal (Figure 1-3).  This is similar to observations in 
U1242 human glioma cells—which endogenously carry a p53 (R175H) DNA binding 
domain mutation—where dual therapy with ATMi and radiation significantly increases 
the frequency of mitotic defects (Figure 1-4).  Yet, while such findings imply that ATMi 
allows p53 mutant gliomas to overcome G2/M arrest and divide before DNA strand 
breaks can be repaired, this has not been confirmed.    
 
1.8 Goals of the Current Study 
The first objective of the current study was to validate the efficacy of a new, third-
generation ATMi, AZ32.  The previous generation of ATMi, KU-60019, is a large 
molecule that is unable to cross the blood brain barrier (BBB), which limits its 
bioavailability (Vecchio et al., 2015).  Thus, its application to glioma therapy would 
require invasive intracranial administration.  AZ32 was identified through a small-
molecule screen for its low molecular weight and ability to cross the BBB.  We assessed 
the effects of AZ32 on signaling downstream of ATM by monitoring phosphorylation of 
various ATM substrates.  We also examined the effects of AZ32 on glioma cell survival 
following radiation.  Next, we studied how p53 status affects cell cycling after radiation 
in otherwise isogenic HCT116 human colon carcinoma cells.  We also attempted to 
generalize the radiosensitizing effects of ATMi on survival in HCT116 cells.  Finally, we 
examined how ATMi affects radiosurvival and mitotic arrest in isogenic glioma cells that 
differ only in p53 status.     
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II. Methods 
 
2.1 Antibodies 
Primary antibodies include anti-p53 (Calbiochem or Santa Cruz DO-1), anti-p-
p53 (Cell Signaling), anti-p-Kap1 (Biosource), anti-Kap1 (Abnova), anti-PLK1 (Novex), 
anti-p-PLK1 (BD Pharmingen), anti-p-Chk2 (Cell Signaling), anti-Chk2 (Cell Signaling), 
anti-α tubulin, (Cell Signaling), and anti-GAPDH (EMD Millipore).  Secondary 
antibodies include DyeLight 800 anti-IgG (Rockland Immunochemicals), Alexafluor 680 
anti-IgG (Invitrogen), Alexafluor 488 anti-IgG (Invitrogen), Alexafluor 568 anti-IgG 
(Invitrogen), and Alexafluor 647 anti-IgG (Invitrogen).   
 
2.2 Reagents 
AZ32 was provided by Astra Zeneca and dissolved in DMSO to concentrations 
specified within text.  KU-60019 was provided by KuDOS Pharmaceuticals and 
dissolved in DMSO at a concentration of 3 µM.   
 
2.3 Cell Culture 
Table 2-1 lists the cell types and derivatives used in experiments.  Cells were grown in 
complete Dulbecco’s Modified Eagles Medium (Gibco) supplemented with 5% FBS and 
penicillin-streptomycin antibiotic solution.  Medium was changed twice a week and cells 
were passaged once a week in trypsin-EDTA.  Cells were grown in incubation at 37ºC 
and 5% CO2.  Experiments were performed 24-72 hours after passaging.   
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U87MG 
U87/sh-p53 (Addgene Plasmid #19119 - shp53 pLKO.1 puro) 
U87MG cells expressing short-hairpin RNA to knock down p53 
p53 Status 
 
U87/luc/RFP 
U87MG cells expressing luciferase and RFP 
(Biddlestone-Thorpe et al., 2013) 
Wild-type 
 U87/luc/RFP/sh-p53 Knockdown 
 
U87/H2B-mCherry 
U87MG cells expressing H2B-mCherry to label chromatin 
Wild-type 
 U87/sh-p53/H2B-mCherry Knockdown 
 
U87/H2B-mCherry/Centrin 2-EGFP 
U87MG cells expressing H2B-mCherry to label chromatin and 
Centrin 2-EGFP to label centrosomes 
Wild-type 
 U87/sh-p53/H2B-mCherry/Centrin 2-EGFP Knockdown 
U1242 
U1242/luc/RFP 
(Biddlestone-Thorpe et al., 2013) 
Mutant (R175H) 
GL261 (Karlin et al., 2014) Mutant (R153P) 
HCT116 
HCT116 p53 +/+ 
HCT116 cells homozygous for wild-type p53 
(Sur et al., 2009) 
Wild-type 
 
HCT116 p53 -/- 
HCT116 cells with p53 knocked out on both alleles 
(Sur et al., 2009) 
Null 
 
HCT116 p53 R248W/- 
HCT116 with p53 knocked out on one allele and R248W mutant p53 
knocked in on the other allele 
(Sur et al., 2009) 
Mutant (R248W) 
 HCT116/H2B-mCherry Wild-type 
Table 2-1: List of cell types and derivatives used in experiments 
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2.4 Western Blotting 
Cells were lysed and harvested in 1x Laemmli buffer (Bio-Rad).  Proteins were 
resolved on 10% polyacrylamide or precast CriterionTM TGX Any-Kd gradient gels and 
transferred on to nitrocellulose or PVDF membranes.  Membranes were blocked in casein 
blocking buffer (Sigma Aldrich) for at least 2 hours, labeled with primary antibody 
(dilution 1:1000 in casein buffer or 5% BSA in TBST) overnight at 4ºC, and secondarily 
labeled with IR fluorophore conjugated anti-IgG antibody (DyeLight 800 diluted in 
casein buffer at 1:5000 or Invitrogen Alexafluor 680 diluted in casein buffer at 1:10000) 
for 2-3 hours at room temperature.  Bands were visualized on a Li-cor Odyssey IR imager 
and densities analyzed using ImageJ. 
 
2.5 Irradiation 
Irradiation was performed using an MDS Nordion Gammacell 40 irradiator with 
Cs-137 source at a dose rate of 1.05 Gy/min. 
 
2.6 Confocal Microscopy 
Cells were grown on 4-chamber slides (Lab-Tek) to 90% confluency.  Cells were 
fixed in 4% paraformaldehyde for 15 min, washed twice in PBS for 5 min, permeabilized 
in 0.5% Triton X-100 for 10 min, and blocked for at least 2 hours in casein/2% goat 
serum.  Primary antibody (dilution 1:500 in casein/2% goat serum) labeling was 
performed at 4ºC overnight.  Slides were washed in PBS, and secondary antibody 
(dilution 1:500 in casein/2% goat serum) labeling was performed at room temperature for 
2-3 hours.   Cell nuclei were counterstained with DAPI (1 mg/mL) and mounted in 
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VECTASHIELD mounting medium (Vector Laboratories).  Imaging was performed on a 
Zeiss LSM 710 laser scanning confocal microscope and images were analyzed using 
Zeiss Zen software.   
 
2.7 Colony Forming Assay 
Cells were grown to confluency in a 6 cm tissue culture dish and passaged in 
trypsin.  Single cells were transferred in to 5 mL of culture media, 0.5 mL of cell solution 
was added to 0.5 mL of trypan blue, and approximate cell concentration was measured by 
counting on a hemocytometer.  Cells were seeded in 6 cm dishes or 6-well plates at 
appropriate numbers.  Cells were allowed 4-5 hours to attach and were either left 
untreated or treated with 3 µM AZ32. Cells were irradiated 30 min to 1 hour after 
addition of AZ32. Medium was changed 16 hours after irradiation.  Medium was 
discarded two to three weeks after irradiation, cells were labelled in 0.5% crystal violet in 
25% methanol, and colonies were counted.  The average colony counts between 
replicates were recorded and compared between different treatment conditions.  Dose 
response curves were constructed by plotting surviving fraction vs. radiation dose.  
Statistical significance of results was calculated using ANOVA in IBM SPSS Statistics 
22 or in GraphPad Prism. 
 
2.8 Live Cell Imaging 
   U87/H2B-mCherry/Centrin 1-EGFP, U87/sh-p53/H2B-mCherry/Centrin 1-
EGFP, U87/H2B-mCherry, or U87/sh-p53/H2B-mCherry cells were seeded on 4-
chamber, glass-bottom CELLview tissue culture dishes (Grenier Bio-One) and allowed to 
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grow for 48-72 hours.  For drug and radiation treatment conditions, 3 µM AZ32 was 
added 30 min to 1 hour before irradiation at 5 Gy.  Still images were taken every 7 min 
for a total of 16 hours beginning 2 hours after irradiation.  Cells were incubated at 37ºC 
and 5% CO2 throughout the imaging period.   
 
2.9 Identification of Aberrant Mitoses 
 Aberrant mitoses were identified visually by morphological abnormalities in 
DNA and/or centrosomes.  DNA was visualized by DAPI stain or by expression of a 
fluorescent histone H2B-mCherry fusion protein.  Centrosomes were fluorescently 
labelled with antibodies against α-tubulin or with a Centrin 2-EGFP fusion protein.  
Abnormal mitoses were identified as previously described (Amé et al., 2009; Lengauer, 
2001; Plug-DeMaggio et al., 2004; Wonsey and Follettie, 2005). For still images, mitotic 
cells with obvious chromosome breaks, abnormal chromatin morphology, and/or 
chromatin bridges were scored as aberrant.  Mitotic cells with more than two centrosomes 
were also scored as aberrant.  For live-cell imaging, nuclei that failed to complete mitosis 
or appeared to fragment during or after mitosis were scored as aberrant. 
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III. Results 
 
3.1 AZ32 Inhibits Phosphorylation of ATM Substrates 
It has been shown that two early generation ATM inhibitors, KU-55933 and KU-
60019, inhibit phosphorylation of p53 (S15) in glioma cells following radiation (Golding 
et al., 2009; Hickson et al., 2004).  In order to assess the ability of AZ32 to inhibit ATM, 
U1242 glioma cells were irradiated at 5 Gy following treatment with AZ32 at 
concentrations of 0, 0.3, 1, or 3 µM.  It was found that AZ32 inhibits phosphorylation of 
p53 in a dose-dependent manner (Figure 3-1).  Furthermore, AZ32 is an equally potent 
inhibitor of p53 phosphorylation as KU-60019.  Following DNA damage, ATM rapidly 
phosphorylates KRAB-associated-protein-1 (Kap1) at serine-824 (White et al., 2012, 
2006).  We examined phosphorylation of p53 and Kap1 in GL261 mouse glioma cell 
extracts.  Western blot shows that AZ32 yields stable inhibition of Kap1 phosphorylation 
even 3 hours after radiation at 3 Gy (Figure 3-2).  In contrast, GL261 cells display 
elevated basal levels of p53 phosphorylation that is not reduced by AZ32, and IR-induced 
phosphorylation of p53 recovers after 3 hours.  This is consistent with the fact that p53 is 
phosphorylated by kinases other than ATM.  Sustained inhibition of ATM signaling by 
AZ32 was also confirmed in human glioma cells.  AZ32-treated and untreated U1242 
human glioma cells were irradiated at 5 Gy and harvested 30 min to 6 hours afterward.  
Phosphorylation of Kap1 (S824) and Chk2 (T68) was assessed by Western blot (Figure 
3-3).  As expected, phosphorylation of Kap1 and Chk2 persists several hours after 
radiation in untreated cells.  In contrast, AZ32 inhibits phosphorylation by ATM even 6 
hours after radiation.  Overall levels of Kap1 and Chk2 were unaffected by AZ32 or IR. 
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Figure 3-1: AZ32 inhibits phosphorylation of p53 in a dose-dependent manner in 
U1242 human glioma cells.   AZ32 was administered at doses of 0, 0.3, 1, and 3µM and 
phosphorylation of p53 was monitored 30 minutes after irradiation at 5 Gy.  Protein band 
densities for phospho-p53 were normalized to levels of GAPDH 
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Figure 3-2: AZ32 inhibits phosphorylation of Kap1 and p53 in a dose-dependent 
manner in GL261 mouse glioma cells.   AZ32 was administered at doses of 0, 0.3, 1, 
and 3 µM 30 min prior to irradiation at 3 Gy. Phosphorylation of ATM targets Kap1 
(S824) and p53 (S15) was monitored 1 and 3 hours after IR.   
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Figure 3-3: AZ32 inhibits ATM signaling several hours after irradiation in U1242 
glioma cells.  U1242 human glioma cells were treated with AZ32 at 3µM 30 min prior to 
irradiation at 5 Gy.  Cells were harvested 30 min, 1 hr, 2 hrs, 4 hrs, or 6 hrs after 
irradiation.  AZ32 effectively inhibits downstream phosphorylation of Kap1 (S824) and 
Chk2 (T68) several hours after irradiation.  NT, No Treatment. 
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3.2 AZ32 Enhances Radiosensitivity of Glioma Cells 
 Early generation ATMis have been shown to enhance radiation sensitivity of 
glioma cells (Biddlestone-Thorpe et al., 2013; Golding et al., 2009, 2012).  The effects of 
AZ32 on radiosensitivity were assessed by clonogenic colony forming assay.  U1242 
cells were treated with AZ32 at 3 µM, irradiated, and allowed to grow for 10 days.  The 
log of surviving fraction was plotted against radiation dose and the data were fit to a 
second order polynomial (Figure 3-4).  It was found that AZ32 significantly 
radiosensitizes U1242 glioma cells at doses as low as 1 Gy.  AZ32 reduced survival by a 
factor of 1.5 at 1 Gy and 3.2 at 2 Gy. 
 
3.3 Mutant p53 Abrogates Cell Cycle Arrest in HCT116 Cells 
 Next, we sought to examine how ATMi and p53 status determine radiosensitivity.  
It was necessary that we work with isogenic cell lines that differ only in p53 status.  
HCT116 human colon carcinoma cells that vary only in p53 status have been well 
validated (Bunz, 1998; Bunz et al., 1999, 2002; Sur et al., 2009).  These cells have been 
used previously to examine the effects of p53 status on cytotoxicity following treatment 
with DDAs (Bunz et al., 1999).  Studies have found that knockout of p53 prevents these 
cells from sustaining G2/M arrest after IR (Bunz, 1998).  We studied if arrest is also 
defective in cells expressing mutant p53 (mp53).  Mp53 HCT116 cells harbor the R248W 
DNA binding domain mutation on one allele and a defective p53 promoter on the other.  
Western blot shows that both wild-type and mp53 are induced after 2 Gy of radiation 
(Figure 3-5).  In contrast, p53 was not induced in p53-null cells.  Mitosis was assessed by 
immunofluorescence.   Wild-type and mp53 HCT116 cells were irradiated at 5 Gy and  
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Figure 3-4: ATM inhibition by AZ32 significantly radiosensitizes U1242 glioma 
cells.  Log plot of surviving fraction vs. radiation dose. Colony forming assay confirms 
that treatment with 3 µM AZ32 significantly reduces survival of U1242 glioma cells 
following irradiation.  The survival reduction factors are 1.5 at 1 Gy and 3.2 at 2 Gy. 
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Figure 3-5: Western blot of irradiated HCT116 cells with different p53 status.  p53 
is induced by irradiation in p53 +/+ and p53 R248W/- HCT116 cells, but not in p53 -/- 
HCT116 cells.  Cells were treated with AZ32 an hour prior to IR at 2 Gy and harvested 
an hour after IR. 
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Figure 3-6: p53 mutant HCT116 cells continue cycling after irradiation.  p53 +/+ or 
mutant p53 R248W/- HCT116 cells were irradiated at 5 Gy and allowed to grow for 48 
hours.  Cells were fluorescently labelled with DAPI and antibodies against α-tubulin.  
While p53 +/+ cells appear to arrest following irradiation, p53 mutant R248W/- cells 
continue to undergo mitosis.  Numerical inserts indicate the proportion of aberrant to total 
mitoses. 
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fixed after 48 hours.  Microtubules were labelled with antibodies against α-tubulin and 
DNA was stained with DAPI.  Mitoses were counted and aberrant events were identified 
by abnormalities in DNA and centrosome morphology.  Mitosis appears normal in 
unirradiated p53 wild-type and mp53 cells (Figure 3-6).  Yet, while p53 wild-type cells 
arrest after IR, mp53 cells continue dividing with a high frequency of aberrant events.  
 
3.4 AZ32 Radiosensitizes Wild-type and p53 Mutant HCT116 Cells 
The observation that cell cycle arrest is defective in irradiated mp53 HCT116 
cells led us to question if IR causes these cells to die by mitotic catastrophe.  Previous 
studies have shown that inhibition of ATM radiosensitizes mp53 gliomas to a greater 
extent than their wild-type counterparts (Biddlestone-Thorpe et al., 2013).  We examined 
if HCT116 cells respond similarly to ATMi.   Results from a colony forming 
radiosurvival assay of wild-type and mp53 HCT116 cells after treatment with 3 µM 
AZ32 are plotted in Figure 3-7.  It is evident that mp53 HCT116 cells are more resistant 
to low doses of IR than their wild-type counterparts.  Yet, while AZ32 significantly 
radiosensitizes both cell lines, the effects are greater in wild-type cells.  At radiation 
doses of 1 and 2 Gy, respectively, AZ32 reduces survival by a factor of 2.2 and 7.5 in 
wild-type cells and 1.7 and 4.6 in mutants.  This is in stark contrast to our group’s 
previous findings in glioma cells.  It is possible that the difference is due to the fact that 
glioma cells display much higher levels of endogenous replicative stress than carcinomas 
(Bartkova et al., 2010).  It may be that constant replicative stress selects for glioma cells 
that are inherently deficient in apoptosis.  In contrast, HCT116 cells are known to depend 
on wild-type p53 for apoptosis following DNA damage (Kaeser et al., 2004).     
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Figure 3-7: ATMi radiosensitizes both wild-type and p53 mutant HCT116/H2B-
mCherry cells.  Log plot of surviving fraction vs. radiation dose. Colony forming assay 
shows that treatment with AZ32 radiosensitizes both wild-type and mutant p53 cells.  
Wild-type HCT116 cells appear to be sensitized to a greater degree than p53 mutants.  
Survival reduction factors for wild-type cells are 2.2 at 1 Gy and 7.5 at 2 Gy.  Survival 
reduction factors for p53 mutants are 1.7 at 1 Gy and 4.6 at 2 Gy. 
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3.5 Short-hairpin RNA Effectively Knocks Down p53 Expression 
 Since HCT116 cells differ from gliomas in their response to ATMi, we sought to 
work with isogenic glioma cell lines that differ only in p53 status.  While our group has 
reported that ATMi sensitizes mp53 cells to a greater degree than wild-type p53 gliomas, 
these studies utilized cell lines in which mp53 was overexpressed from a viral vector 
(Biddlestone-Thorpe et al., 2013).  As such, it is unclear whether the effects of ATMi on 
radiosurvival are solely a product of p53 status or if they also depend on the levels of 
mp53 expression.  To construct a more appropriate model for study, U87 and U87/luc-
RFP cells were infected with a retrovirus expressing a short-hairpin RNA targeting p53 
(sh-p53).  Western blot confirms that protein levels of p53 are significantly lower in cells 
expressing sh-p53 (Figure 3-8).  Examination of p53 levels in individual U87/sh-p53 
clones led to selection of clone D1 for downstream studies (Figure 3-8B).  To compare 
p53 expression and phosphorylation between U87 and D1 U87/sh-p53 clones, cells were 
irradiated at 5 Gy and extracts were subject to Western blot (Figure 3-9).  It was 
confirmed that post-IR levels of whole and phospho-p53 are significantly reduced in D1 
clones relative to their wild-type U87 counterparts.  
 
3.6 p53 Knockdown Enhances Glioma Radiosensitivity with AZ32 
 We compared the effects of ATMi on radiosurvival between wild-type and p53 
knockdown U87 glioma cells.  Western blot confirms that phosphorylation of p53 (S15) 
following irradiation is significantly reduced in U87 cells with wild-type p53 and almost 
completely abrogated in those expressing short-hairpin RNA against p53 following 
treatment with 3 µM AZ32 (Figure 3-10).  In order to determine if p53 status affects 
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Figure 3-8: Short-hairpin-p53 cells display effective knockdown of p53.  Protein 
levels show that p53 is effectively knocked down in A) U87/luc/RFP/sh-p53 cells, and B) 
different U87/sh-p53 clones.  In (A), cells were irradiated at 5 Gy and harvested 3 hours 
after IR.  Relative densities for p53 are recorded under each lane.  Band densities were 
normalized to levels of GAPDH. 
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Figure 3-9: Short-hairpin-p53 U87 clone D1 displays effective knockdown of p53.  
Protein levels of p53 and phospho-p53 (S15) show that p53 is effectively knocked down 
in U87/sh-p53 clone D1.  Cells were irradiated at 5 Gy and harvested 30 minutes or 4 
hours after IR.  Relative densities for p53 and phospho-p53 are recorded under each lane.  
Band densities were normalized to levels of GAPDH. 
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Figure 3-10: AZ32 inhibits S15 phosphorylation of p53 in p53 wild-type and p53-
knockdown cells.  Protein levels show that p53 is effectively knocked down in 
U87/luc/RFP/sh-p53 cells and that AZ32 inhibits accumulation of phospho-p53 (S15) 
following IR.  Cells were treated with AZ32 an hour prior to irradiation at 5 Gy and 
harvested 3 hours after IR. 
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radiosensitization by ATMi, clonogenic radiosurvival assays were performed on U87 and 
U87/sh-p53 cells (Figure 3-11).  We found that AZ32 radiosensitizes U87/sh-p53 cells to 
a much greater degree than wild-type U87 cells.  In wild-type cells, AZ32 reduced 
survival by a factor of 1.1 at 1 Gy and 1.3 at 2 Gy.  In sh-p53 cells, AZ32 reduced 
survival by a factor of 2.1 at both 1 and 2 Gy.  Thus, the radiosensitizing effects of ATMi 
depend on p53 status in U87 glioma cells. 
 
3.7 p53 Knockdown and AZ32 Enhance Mitotic Catastrophe in Irradiated Glioma 
 The mechanism by which p53 status and ATMi interact to determine glioma 
radiosensitivity remains unclear.  Studies have shown that inhibition of ATM-dependent 
signaling through the p38MAPK-MK2 pathway induces mitotic catastrophe in p53-
defective cells treated with doxorubicin (Reinhardt et al., 2007).  Thus, we explored if 
ATMi results in aberrant cycling in irradiated sh-p53 glioma cells.  In order to a follow 
mitosis, U87 and U87/sh-p53 cells were infected with lentiviruses expressing 
fluorescently tagged histone H2B and Centrin 2.  H2B-mCherry labels chromatin, while 
Centrin 2-EGFP labels centrosomes.  Cells were treated with 3µM AZ32 30 minutes 
prior to irradiation at 5 Gy.  Mitosis was monitored by live-cell imaging on a spinning 
disc confocal microscope.  Total and aberrant mitoses were counted visually and mitotic 
statistics recorded (Table 3-1).  Representative images of normal and aberrant mitoses are 
provided in Figure 3-12.  AZ32 greatly increases the frequency of aberrant mitoses only 
in cells in which p53 was knocked down.  While there were only 1-3 instances of 
aberrant mitoses among wild-type and untreated U87/sh-p53 cells, 16 aberrant mitoses 
were identified in U87/sh-p53 cells treated with AZ32.   
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Figure 3-11: ATM inhibition by AZ32 significantly radiosensitizes U87/sh-p53 
glioma cells.  Log plot of surviving fraction vs. radiation dose. Colony forming assay 
confirms that treatment with 3 µM AZ32 radiosensitizes U87/sh-p53 glioma cells to a 
greater degree than wild-type U87 cells. Survival reduction factors for wild-type cells are 
1.1 at 1 Gy and 1.3 at 2 Gy.  Survival reduction factors for p53 mutants are 2.1 at 1 Gy 
and 2.1 at 2 Gy. 
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Figure 3-12: ATMi increases the rate of mitotic catastrophe in glioma cells when 
p53 is knocked down.  Time series of mitosis in U87/Centrin-EGFP/H2B-mCherry and 
U87/sh-p53/Centrin-EGFP/H2B-mCherry cells.  Treatment with 3 µM AZ32 does not 
appear to greatly increase the frequency of aberrant mitoses in p53 wild-type cells, but 
does in sh-p53 cells.   
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Table 3-1: Mitotic statistics for irradiated U87/Centrin-EGFP/H2B-mCherry cells  
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IV. Discussion and Future Directions 
 
4.1 AZ32: From Bench to Clinic 
 Despite recent advances, survival rates for patients with glioblastoma multiforme 
remain dismal.  Radiotherapy is an essential part of first-line treatment for GBM, but 
side-effects and inherent neurotoxicity remain significant drawbacks.  In addition, 
gliomas tend to be highly aggressive and resistant to radiation.  Indeed, it has been shown 
that glioma-derived cancer stem cells can preferentially activate DNA damage 
checkpoints and repair mechanisms to promote radioresistance (Bao et al., 2006).  
Therefore, targeting proteins involved in the DNA damage response may be a useful 
strategy for improving the efficacy of radiotherapy.  
 
 ATM kinase is the primary protein involved in signaling DNA double-strand 
breaks.  Its substrates include a variety of proteins involved in cell cycle checkpoints and 
DNA repair (Matsuoka et al., 2007).    As discussed in previous sections, 
pharmacological inhibition of ATM potently sensitizes glioma cells and tumors to 
ionizing radiation (Biddlestone-Thorpe et al., 2013; Golding et al., 2009, 2012).  This is 
promising, because clinical adoption of ATMi could reduce the effective radiation dose 
necessary to kill tumor cells.  This in turn could yield significant improvements in the 
length and quality of life for GBM patients.  Therefore, the identification and validation 
of stronger, more specific ATM inhibitors is critical.   
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A next-generation ATMi, AZ32, was identified in a high-throughput molecular 
screen as a low-weight compound with enhanced blood brain barrier (BBB) penetration 
(Karlin et al., 2014).  This work has validated the efficacy of AZ32 in human glioma cells 
by monitoring radiation-induced phosphorylation of Kap1, Chk2, and p53.  These 
proteins are essential components of the DDR and, as such, are rapidly phosphorylated by 
ATM in response to ionizing radiation (Banin et al., 1998; Ward et al., 2001; White et al., 
2012, 2006). We found that ATM inhibition by AZ32 is dose dependent and appears to 
be prominent even several hours after IR.  In addition, AZ32 was found to be an equally 
potent inhibitor of ATM signaling as its predecessor, KU-60019.  This is significant, 
because while KU-60019 has been established as a strong and specific ATM inhibitor, it 
is unable to cross the BBB (Vecchio et al., 2015).   Thus, AZ32 offers enhanced 
bioavailability without sacrificing strength.  We also confirmed that AZ32 significantly 
reduces radiosurvival of human glioma cells.  Current clinical guidelines for GBM 
radiotherapy call for administration of daily 2 Gy fractions for a total of 40-60 Gy (Ghose 
et al., 2010).  Our results are promising, because AZ32 significantly enhances glioma 
radiosensitivity at doses as low as 1 Gy.  Such evidence suggests that clinical adoption of 
AZ32 could potentially lower the radiation dose necessary to combat GBM tumors. 
 
 Before transitioning to the clinic, further research is necessary to elucidate upon 
the pharmacological and biological properties of AZ32.  For example, researchers have 
yet to assess AZ32’s stability.  Furthermore, it has been reported that serum greatly 
reduces the potency and bioavailability of the previous-generation ATMi, KU-60019 
(Golding et al., 2012).  Thus, it is critical to confirm AZ32’s serum stability and efficacy.  
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It is also essential that future studies elaborate on AZ32’s in vivo pharmacokinetics.  This 
includes measures of bioavailability, circulatory and tissue distribution, BBB penetration, 
and excretion.  It would be particularly valuable to assess if AZ32 can be administered 
non-invasively without any deleterious off-target side effects.  It is also necessary to 
elaborate on tolerance and relative toxicity.  Most importantly, research must validate the 
in vivo efficacy of AZ32 in radiosensitizing GBM tumors.  This includes measuring 
effects on actual tumor size, growth, and persistence, as well as overall survival in 
animals.  Indeed, our group has already shown that AZ32 administered with radiotherapy 
significantly increases survival in GL261 mouse glioma models and is in the process of 
further validating its effects in vivo (Karlin et al., 2014).   Future work should also focus 
on examining if ATMi treatment can sensitize other cancers to DDAs.  In addition, it is 
crucial to elaborate on how inhibition of ATM affects radiosensitivity of normal tissue, 
and whether such interactions have implications for clinical adoption of ATMi in cancer 
therapy. Finally, studies should elaborate on the molecular and physiological mechanisms 
that underlie radiosensitization by ATMi.  
  
4.2 Linking Mitotic Catastrophe to Radiosurvival 
While ATMi effectively sensitizes glioma cells to radiation, how it does so 
remains a mystery.  It is also unclear why defects in p53 enhance these radiosensitizing 
effects.  Studies have shown that ATM-dependent signaling through the p38MAPK-MK2 
pathway is essential for G2/M arrest in p53-null mouse embryonic fibroblasts (MEFs), 
and that disruption of this pathway results in cell death by mitotic catastrophe (Reinhardt 
et al., 2007). This suggests that ATMi overrides G2/M arrest in cells with defective p53, 
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thus reducing radiosurvival by promoting mitotic catastrophe.  We began testing this 
hypothesis in isogenic HCT116 cells expressing the R248W DNA-binding-domain 
mutant form of p53.  Others have shown that disruption of p53 sensitizes these cells to IR 
and other DDAs (Bunz et al., 1999).  Another report by the same group indicates that 
p53-null HCT116 cells fail to arrest the cell cycle after IR (Bunz, 1998).  We confirmed 
that mp53 HCT116 cells are also unable to inhibit mitosis after IR.  Contrary to 
expectations though, aberrant mitotic entry did not translate to reduced radiosurvival.  In 
fact, we found that mp53 cells were significantly more radioresistant than wild-type 
HCT116 cells.  Furthermore, ATMi was more effective at radiosensitizing p53 wild-type 
cells than their mp53 counterparts.  
 
These observations are in stark contrast to our group’s previous findings in glioma 
cells (Biddlestone-Thorpe et al., 2013).  We suspect that this difference may be due to the 
fact that basal levels of replicative stress are significantly higher in gliomas than in 
cancers derived from epithelial tissues (Bartkova et al., 2010).  Indeed, neither wild-type 
nor p53-deficient HCT116 cells appear to display any significant degree of inherent 
genetic instability (Bunz et al., 2002).  It may be that wild-type p53 induces apoptosis in 
response to replicative stress in HCT116 cells, but that such mechanisms are inactive in 
glioma.  Indeed, previous reports indicate that gliomas are often highly resistant to death 
by apoptosis (Eisele and Weller, 2013; Steinbach and Weller, 2004).  Thus, it is possible 
that ATM inhibition in irradiated HCT116 cells reduces repair of DSBs, stimulating 
apoptosis through p53-dependent signaling.  This would enhanced radioresistance in 
mp53 background.  Yet, the Vogelstein group has shown that deletion of p53 in HCT116 
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cells sensitizes them to apoptosis after treatment with IR and other DDAs (Bunz et al., 
1999).  The authors suggest that this is due to reduced p21 expression, but cells 
expressing R248W-mp53 also appear to be defective in p21 induction and, therefore, 
should exhibit a phenotype similar to p53-null cells (Song et al., 2007; Sur et al., 2009; 
Wohak et al., 2014).  An alternate theory is that the reduced responsiveness of mp53 
HCT116 cells to ATMi is due to the fact that ATM signaling is already partially defective 
in these cells.  Indeed, HCT116 cells harbor an intrinsic mutation in Mre11, which results 
in defective signaling through ATM and Chk2 (Takemura et al., 2006).  It has also been 
shown that MEFs expressing R248W-mp53 are unable to efficiently recruit ATM to sites 
of DSBs due to defects in the Mre11-Nbs1-Rad50 complex (Song et al., 2007).  Finally, 
it may be that the observed effects are due to inherent differences in signaling between 
different p53 mutants.  Our group’s previous studies utilized glioma cells overexpressing 
D281G-mp53.  It has been documented that different p53 mutants vary in their ability to 
transactivate target genes and interact with protein binding partners (Freed-Pastor and 
Prives, 2012; Kang et al., 2013; Muller and Vousden, 2013).  Therefore, it may be that 
structural and functional differences between R248W and D281G-mp53 alter sensitivity 
to radiation and ATMi.   
 
Given the possibility that DDR signaling and dominant modes of cell death differ 
between colon carcinomas and gliomas, we sought to work with isogenic glioma cells 
that differ only in p53 status.  Previous results from our group indicate that mp53 gliomas 
are more sensitive to IR than their wild-type counterparts in the presence of ATMi, but 
these studies were performed in cells in which mp53 was overexpressed.  Thus, it 
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remains unclear if ATMi’s radiosensitizing effects are due to p53 status, or if 
overexpression is a confounding variable.  Therefore, we selected glioma cell clones 
expressing short-hairpin RNA against p53.  The parental U87 glioma cell line is the same 
one used in the previous study showing ATMi preferentially sensitizes p53 mutants to IR.  
We found that radiosurvival does not vary significantly between sh-p53 and wild-type 
U87 glioma cells.  It was also confirmed that radiosensitization by ATMi is enhanced in 
cells in which p53 is knocked down.  Finally, time-lapse imaging following IR revealed 
that ATMi does preferentially increase the rate of mitotic catastrophe in sh-p53 cells.  As 
previously mentioned, our group has shown that G1/S arrest is defective in mp53 
gliomas, while G2/M arrest appears intact (Biddlestone-Thorpe et al., 2013).  The current 
findings support the theory that ATM is necessary for p53-independent G2/M arrest.   
 
The molecular mechanisms underlying our observations remain unclear, but it has 
been suggested by the Yaffe group that ATM-mediated activation of the p38MAPK-MK2 
pathway is necessary for G2/M arrest in p53-deficient cells (Reinhardt et al., 2007).  
Furthermore, inactivation of MK2 results in mitotic catastrophe in p53-null MEFs 
following treatment with DDAs cisplatin and doxorubicin.  The same group showed that 
doxorubicin results in translocation of the p38/MK2 complex from the nucleus to the 
cytoplasm within an hour of treatment (Reinhardt et al., 2010).  Specifically, 
phosphorylation of MK2 (T334) appears to be necessary for exposing a nuclear export 
signal (Ben-Levy et al., 1998; Meng et al., 2002; White et al., 2007). Once in the 
cytoplasm, MK2 phosphorylates a variety of proteins involved in binding and degrading 
GADD45α mRNA, increasing its expression.  GADD45α, in turn, binds to Cdc25B and 
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Cdc25C, sequestering them to the cytosol and preventing aberrant mitotic entry.  ATM’s 
direct involvement with this pathway remains unclear, but it has been suggested that 
signaling through the thousand-and-one kinases (TAOKs) may underlie the interaction 
(Beckta et al., 2014).  The TAOKs directly activate MAPK kinases MEK3 and MEK6, 
which phosphorylate and active p38MAPK.  Indeed, TAOKs themselves are directly 
phosphorylated by ATM after IR (Raman et al., 2007).  Thus, ATM-mediated activation 
of p38 by the TAOKs may contribute to efficient G2/M arrest in p53-deficient cells.   
 
Intriguingly, it has been reported that nuclear signaling through p38 and MK2 is 
required for proper mitosis through an interaction with Plk1 (Tang et al., 2008).  The 
authors found that Plk1 colocalizes with p38 and MK2 at spindle poles during prophase 
and metaphase and that MK2 phosphorylates Plk1 at serine-326 both in vitro and in vivo.  
In addition, p38 or MK2 depletion or expression of a Plk1 mutant (S326A) was sufficient 
to induce mitotic arrest.  Mitotic arrest by p38 or MK2 inactivation was reversed only in 
cells expressing the Plk1 phospho-mimetic mutant (S326E).  As mentioned previously, 
Plk1 promotes mitotic entry by facilitating nuclear translocation of Cdc25c and Cdc25b 
phosphatases (Lobjois et al., 2009; Toyoshima-Morimoto et al., 2002).  Plk1 also appears 
to be necessary for recovery from G2/M arrest and its expression is elevated in cells 
lacking wild-type p53 (Macůrek et al., 2008; Sur et al., 2009).  Furthermore, p53 
represses Plk1 expression by directly binding its promoter, and a physical interaction 
between Plk and p53’s DNA binding domain reduces transcription of p53-target genes 
(Ando et al., 2004; McKenzie et al., 2010).  
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In conclusion, our findings and the literature suggest that cell cycle arrest in 
response to DNA damage depends on a complex interplay between ATM, the TAOKs, 
p38MAPK, MEK3/6, MK2, p53, and Plk1.  Signaling through these pathways converges 
on the Cdc25 phosphatases, resulting in their cytosolic sequestration and inhibition of 
mitosis.  Figure 4-1 outlines a possible model of the various signaling components that 
contribute to G2/M arrest.  Theoretically, disruption of signaling through ATM, TAOKs, 
MEK3/6, p38, or MK2 should abrogate G2/M arrest in p53-deficient cells.  Importantly, 
it is necessary to assess if targeting TAOKs and downstream MEK3/6 can sensitize 
cancer cells to IR and other DDAs.  In addition, future studies should elaborate upon the 
role of Plk1 in G2/M arrest and checkpoint reversal.  Our group has already begun work 
in glioma cell lines overexpressing Aurora kinase A (AURKA), the kinase necessary for 
activating Plk1 and stimulating mitosis and checkpoint recovery (Bruinsma et al., 2014; 
Macůrek et al., 2008).  We expect that cells overexpressing AURKA will display 
increased signaling through Plk1, causing them to behave more like p53 mutants in their 
sensitivity to DDAs and cell cycling.  Finally, it is necessary to elaborate upon the 
variation between glioma and colon carcinoma cells in their response to ATMi.  It would 
be interesting to explore how these cells differ in p53-dependent apoptosis.  Specifically, 
it would be useful to analyze how expression of p53 targets involved in apoptosis varies 
between p53-null and mutant U87 and HCT116 cells.  It would also be of value to assess 
the functionality and fidelity of the MRN-complex in recruiting ATM to sites of DSBs in 
glioma cells, since such mechanisms appear to be defective in colon carcinoma.  Indeed, 
elucidating upon how various signaling mechanisms interact to determine cell death in 
different cancers would be useful for identifying pathways to target for new therapies. 
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Figure 4-1: An expanded model of G2/M Arrest following DNA damage.  Both p53 
and ATM contribute to G2/M arrest in normal cells.  ATM signaling ultimately results in 
phosphorylation of Cdc25, which stimulates binding by 14-3-3 and subsequent nuclear 
export.  Activation of p38 by MEK3/6 results in phosphorylation of MK2 on threonine 
334, exposing a nuclear export signal.  Cytoplasmic MK2 promotes expression of 
GADD45α, which binds and inhibits Cdc25.  p53 inhibits transcription of Plk1 and 
stimulates transcription of proteins that sequester Cdc25 to the cytosol, sustaining mitotic 
arrest.  In the absence of p53, Plk1 levels remain high and nuclear export of p38 and 
MK2 is necessary to sustain G2/M arrest.  ATM or p38/MK2 inhibition in p53 mutants 
promotes mitotic catastrophe.  Arrows: Black = Activation/Phosphorylation; Red = 
Inhibition; Blue = Translocation  
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